Viking Therapeutics secures $575 million through a dual-offering of stock and convertible notes, strengthening its cash position for ongoing clinical development despite shareholder dilution.
Viking Therapeutics closed upsized offerings of common stock and convertible senior notes, raising approximately $575 million in gross proceeds, which strengthens its cash position but dilutes existing shareholders.
Viking Therapeutics has successfully closed an upsized offering of common stock and convertible senior notes, securing approximately $575 million in gross proceeds. The capital injection significantly bolsters the clinical-stage biopharmaceutical firm's balance sheet as it advances its metabolic and endocrine disorder pipeline.
The company closed an upsized offering consisting of both common stock and convertible senior notes.